6515--Oncology Reagents

SOL #: 36C26226Q0691Sources Sought

Overview

Buyer

Veterans Affairs
Veterans Affairs, Department Of
262-NETWORK CONTRACT OFFICE 22 (36C262)
Gilbert, AZ, 85297, United States

Place of Performance

Los Angeles

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

PSC

Medical And Surgical Instruments, Equipment, And Supplies (6515)

Set Aside

No set aside specified

Timeline

1
Posted
Apr 23, 2026
2
Response Deadline
May 1, 2026, 10:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Department of Veterans Affairs (VA), specifically the VISN 22 Network Contracting Office, is conducting a Sources Sought / Request for Information (RFI) to identify potential sources for Oncology Reagents for the Greater Los Angeles VA Healthcare System. This RFI is for market research and planning purposes only and does not constitute a solicitation. Responses are due by May 1, 2026.

Scope of Work & Salient Characteristics

The VA is seeking oncology supplies and reagents that, at a minimum, meet the following specifications:

  • Capable of detecting wild type (Negative) from Mutated (Positive) genes.
  • Must test DNA extracted from whole blood or bone marrow samples using a reverse transcription-polymerase chain reaction (RT-PCR) based method or High-Resolution Melt (HRM) Analysis.
  • Capable of determining DNA quantity by measuring optical density (OD) at 260 nm.
  • Resultant DNA must be dilutable to a concentration of 5 ng/µl in 1x TE buffer at pH 8.0.
  • Resultant DNA must be storable at +4 to +8°C for 1 week or at –20°C for longer term storage.
  • Real-time (qPCR) reaction must be optimized for DNA samples containing 25 ng purified genomic DNA.
  • The limit of detection (LOD) shall be 0.061%.
  • Reagents must be storable at -15°C to -30°C.
  • Minimum reagent shelf life of one year upon receipt.
  • A specific brand mentioned for reference is the Ipsogen JAK2 MutaQuant Kit (Product # 673513), with a quantity of 77 kits (each containing 24 reagents).

Contract & Timeline

  • Type: Sources Sought / Request for Information (RFI)
  • Set-Aside: None specified (market research stage, seeking business size information)
  • Response Due: May 1, 2026, at 3:00 P.M. Pacific Time
  • Published: April 23, 2026

Submission Requirements

Interested and capable sources should provide:

  • Company name, address, and point of contact.
  • Business size status (e.g., SDVOSB, VOSB, HUBZone, WOSB, Large Business).
  • Confirmation of small business status under NAICS 325413 (1250 Employees).
  • Whether the company is a manufacturer or distributor, and the country of origin.
  • If a distributor, details on any alteration, assembly, or modification of items.
  • Information on existing federal contracts (GSA FSS, NAC, NASA SEWP, etc.) and if the referenced items are available.
  • General pricing for market research purposes.
  • Company DUNS number.
  • Capabilities demonstrating that "equal to items" meet all required salient characteristics, with clear, compelling, and convincing evidence.

Important Notes

This RFI is for information and planning purposes only and does not constitute a solicitation. Responses are not offers and cannot form a binding contract. All expenses for responding are the responsibility of the responder. A future solicitation may be published, but responses to this RFI are not considered adequate for that. This notice is not a request to be added to a bidders list.

People

Points of Contact

Carabon, KalContract SpecialistPRIMARY

Files

Files

Download

Versions

Version 1Viewing
Sources Sought
Posted: Apr 23, 2026
6515--Oncology Reagents | GovScope